Clinical Trials · NCT00051558

Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

CompletedPhase 3Teriparatide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
428
Start date
Nov 2002
Locations
15 sites, 6 countries
Primary endpoint
Change From Baseline at 18 Month Endpoint in Lumbar Spine Bone Mineral Density (BMD)
View Teriparatide compound reference